Company news
Arrowhead Pharmaceuticals, Inc. news in 2022
Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
December 20, 2022
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
December 19, 2022
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 7, 2022
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 7, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
November 27, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
November 20, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
November 13, 2022
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
November 8, 2022
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
November 6, 2022
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
October 10, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
August 31, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
August 16, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
August 3, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
July 19, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
July 4, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
June 6, 2022
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 25, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 9, 2022
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
May 8, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences
May 1, 2022
Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors
May 1, 2022
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
April 26, 2022
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
April 25, 2022
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
April 24, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
April 19, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences
March 31, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
March 23, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
March 14, 2022
Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia
February 23, 2022
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
February 17, 2022
Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022
February 16, 2022
Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results
February 1, 2022
Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
January 23, 2022
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results
January 20, 2022
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
January 11, 2022
Calls in 2022
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q4 2022 Earnings Call
Nov 28, 2022
Transcript - Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2022 Earnings Call
Aug 4, 2022
Transcript - Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2022 Earnings Call
May 10, 2022
Transcript - Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2022 Earnings Call
Feb 2, 2022
Transcript
Decks in 2022
- Technical Presentation (2022)
Technical · 11 slides · 2022